Immunotherapy of Disease

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Immunology and Medicine Series

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-94-009-1844-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful treatment of refractory autoimmune haemolytic anaemia by plasmapheresis.

  2009cited by this paper
• [Blood transfusion and transplantation].

  1991cited by this paper
• Cyclosporine A in psoriasis.

  1991cited by this paper
• [Cyclosporine and psoriasis].

  1991cited by this paper
• The effect of food on cyclosporine absorption.

  1991cited by this paper
• Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914.

  1990cited by this paper
• [Plasma exchange].

  1989cited by this paper
• Removal of neuroblastoma cells from bone marrow by a direct monoclonal antibody rosetting technique.

  1989cited by this paper
• Adoptive cellular therapy of renal carcinoma.

  1989cited by this paper
• Marrow purging for autologous bone marrow transplantation.

  1989cited by this paper
• Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.

  1989cited by this paper
• Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.

  1988cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

  1988cited by this paper
• Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.

  1988cited by this paper
• Interleukin‐2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients

  1988cited by this paper
• Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

  1988cited by this paper
• EXPRESSION OF HLA ANTIGENS ON RENAL TUBULAR CELLS IN CULTURE II. EFFECT OF INCREASED HLA ANTIGEN EXPRESSION ON TUBULAR CELL STIMULATION OF LYMPHOCYTE ACTIVATION AND ON THEIR VULNERABILITY TO CELL‐MEDIATED LYSIS

  1988cited by this paper
• Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy.

  1987cited by this paper
• Interleukin 2 enhances cytotoxic cell function in vitro after T‐cell depleted marrow transplantation

  1987cited by this paper
• Oral contraceptive interaction with cyclosporin.

  1987cited by this paper
• Plasma exchange in severe gastrointestinal and renal forms of Henoch-Schönlein purpura and primary IgA nephropathy. Review of the literature and results of a french retrospective study

  1987cited by this paper
• Interleukin 2 high-affinity receptor expression requires two distinct binding proteins

  1987cited by this paper
• Redesigning nature's poisons to create anti-tumor reagents.

  1987cited by this paper
• Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

  1987cited by this paper
• Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients.

  1987cited by this paper
• Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.

  1987cited by this paper
• The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins.

  1987cited by this paper
• Separation and functional studies of the human lymphokine-activated killer cell.

  1987cited by this paper
• Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

  1987cited by this paper
• Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.

  1987cited by this paper
• Australian multicentre trial in cadaver renal transplantation comparison of short- and long-term cyclosporine A therapy with conventional therapy.

  1987cited by this paper
• Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.

  1987cited by this paper
• Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin

  1987cited by this paper
• Sequential antilymphoblast globulin and cyclosporine for renal transplantation.

  1987cited by this paper
• Cyclosporin in pulmonary sarcoidosis.

  1987cited by this paper
• Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody.

  1987cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Differences between the activities of human monoclonal IgG1 and IgG3 subclasses of anti-D(Rh) antibody in their ability to mediate red cell-binding to macrophages.

  1987cited by this paper
• Cancers following cyclosporine therapy.

  1987cited by this paper
• Effect of HLA matching in 10,000 cyclosporine-treated cadaver kidney transplants.

  1987cited by this paper
• Improved kidney graft survival in nontransfused recipients.

  1987cited by this paper
• Pancreas Transplant Registry Report – 1986

  1987cited by this paper
• The requirements for successful immunotherapy of intraperitoneal cancer using interleukin‐2 and lymphokine‐activated killer cells

  1987cited by this paper
• Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.

  1987cited by this paper
• INFLUENCE OF ENDOTOXIN ON GRAFT‐VERSUS‐HOST DISEASE AFTER BONE MARROW TRANSPLANTATION ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS IN MICE

  1987cited by this paper
• Plasma exchange therapy in progressive systemic sclerosis

  1987cited by this paper
• Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.

  1987cited by this paper
• Plasma exchange for dermatomyositis and polymyositis. Retrospective study of 41 courses of plasma exchange

  1987cited by this paper
• Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement.

  1987cited by this paper
• Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection

  1987cited by this paper
• Monoclonal anti-IL-2 receptor antibody in primate renal transplantation.

  1987cited by this paper
• Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.

  1987cited by this paper
• Plasma exchange in the management of pemphigus

  1987cited by this paper
• Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

  1987cited by this paper
• Islet cell transplantation in type I diabetes mellitus.

  1987cited by this paper
• Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

  1987cited by this paper
• Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.

  1987cited by this paper
• Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

  1987cited by this paper
• Quadruple therapy for cadaver renal transplantation.

  1987cited by this paper
• Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.

  1987cited by this paper
• Limitations to the killing of tumours using radiolabelled antibodies.

  1987cited by this paper
• Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy.

  1987cited by this paper
• Dermatologic changes associated with interleukin 2 administration.

  1987cited by this paper
• Cyclosporine conversion.

  1987cited by this paper
• Biotransformation and distribution in blood of cyclosporine and its metabolites.

  1986cited by this paper
• Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

  1986cited by this paper
• Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.

  1986cited by this paper
• Functional characterization of T lymphocytes propagated from human lung carcinomas.

  1986cited by this paper
• [Heart and heart-lung transplantation].

  1986cited by this paper
• Does the binding of cyclosporine to calmodulin result in immunosuppression?

  1986cited by this paper
• Cyclosporine in allogeneic bone marrow transplantation.

  1986cited by this paper
• Cyclosporine experience in renal transplantation in children.

  1986cited by this paper
• Long-term results of cyclosporine treatment in renal transplantation.

  1986cited by this paper
• Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

  1986cited by this paper
• Evaluation of Toxic Effects following Administration of Monoclonal Antibody MBr1 in Patients with Breast Cancer

  1986cited by this paper
• Renal tubular function in cyclosporine-treated patients.

  1986cited by this paper
• Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

  1986cited by this paper
• Cyclosporine A: a clinical evaluation of drug interactions.

  1986cited by this paper
• Use of the Donor Specific Transfusion Protocol in Living‐Unrelated Donor‐Recipient Combinations

  1986cited by this paper
• MLC-inhibiting antibodies in mice after blood transfusions.

  1986cited by this paper
• Absorption of cyclosporine A after oral dosing.

  1986cited by this paper
• Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients.

  1986cited by this paper
• Cyclosporin interaction with danazol and norethisterone.

  1986cited by this paper
• The transfusion effect.

  1986cited by this paper
• Cyclosporin in frequently relapsing minimal change nephrotic syndrome.

  1986cited by this paper
• Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

  1986cited by this paper
• In vivo anti‐tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN‐γ, on a syngeneic murine melanoma

  1986cited by this paper
• Lymphokine-activated killer cells. Analysis of progenitors and effectors

  1986cited by this paper
• Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

  1986cited by this paper
• Side effects of cyclosporin A treatment in patients with rheumatoid arthritis.

  1986cited by this paper
• Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells.

  1986cited by this paper
• Long-term skin allograft survival after short-term cyclosporin treatment in a patient with massive burns.

  1986cited by this paper
• Plasmapheresis: An adjunct to medical management of severe hyperthyroidism

  1986cited by this paper
• Intraperitoneal administration of interleukin-2 in patients with cancer.

  1986cited by this paper
• Cyclosporin and idiopathic nephrotic syndrome.

  1986cited by this paper
• Cryoglobulinaemia: clinical features and response to treatment.

  1986cited by this paper
• ALG treatment of steroid-resistant rejection in patients receiving cyclosporine.

  1986cited by this paper
• Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin-azathioprine.

  1986cited by this paper
• Inhibition of MHC product induction may contribute to the immunosuppressive action of ciclosporin.

  1986cited by this paper

• Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy

  2011cites this paper
• Debate: Transfusing to normal haemoglobin levels will not improve outcome

  2001cites this paper